Replies to post #239271 on Amarin Corp Plc (AMRN)

[ML888]

I much prefer a operator like JT who is abundantly cautious with disclosures (as he did telling street about Adcom right away) than the alternative. The day to day action does get frustrating, but we have an amazing CEO.

[massulo52]

You think that there were lawsuits before... Beware now, do to his stupidity

[james murphy]

Agree BioChica.I cant believe X Ceo JZ who said we had more BO offers from BP than we had employees[13] and sold his shares before we tanked from $13 to 78c.He is the man who has all the patents in his name for Amrnand he decides to sell almost all his shares in the middle of a Court case deciding if the patents are legit. WE owe this company NOTHING

[biotechtrader2020]

> insiders(B.M's) are executing/selling options hand over fist.
The insider sales are pre-arranged plans. They are reducing their own risk exposure. This also means that their skin in the game is less with each sales milestone.

> I'm a little peeved with J.T's release of spending guidance. Why even do this?
Somethings to consider:
1) Ramping up salesforce costs money.
2) Even if you double the salesforce, prescriptions won't double right away - you need to give them time to ramp up.
Because of 1) and 2) expenses for the upcoming quarter would be high while revenue might not increase as high as our expectations (i.e, not $1 billion for this year like most of our projections before JT's guidance)
3) It is surprising that in spite of R-IT success, vascepa is not in tier 1 or tier 2. May be they missed a cut off date from these insurance companies - either due to pdufa delay or due to their own internal inefficiencies.

For these reasons, JT's guidance of 600M-700M seems reasonable and it is best to get all this news out now in order to stop FUD later.

But I also understand your irritation with the management. As the share price declines, we can come up with hundred kool-aid excuses like
a) delayed filing in europe is great news
b) having tier 3 coverage is the best
c) slow sales ramp is great
d) more partners like HLS and 3 million milestone payments are wonderful.
e) option expiry is the reason for the current price drop
f) market makers are shaking the tree (whatever garbage that is) to get rid of weak hands
g) Thanks for the cheap shares and I am loading up the truck.


AMRN management has accomplished a lot to get the company to where it is today. However, there are areas where AMRN should have excelled in execution if they are to succeed as a standalone company.

In the trailing 12 months as of MRQ, AMRN spent $420M (on a revenue of $363M). The least they could have done is spend a few more millions to make sure that
a) Europe approval was done in parallel with R-IT (don't give me the BS that they need to file million pages - throw more people at it and get this done).
b) Have a big team of people to follow up on insurance timelines and get vascepa into the best possible tier across all providers - hire and do whatever it takes to get this done on time.


I hope some of the mis-steps in execution are not real mis-steps and were done because they are negotiating a european partnership or buyout with a larger pharma.